Daré Bioscience (NASDAQ:DARE) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell?

Daré Bioscience, Inc. (NASDAQ:DARE) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.29 and traded as low as $2.88. Daré Bioscience shares last traded at $2.89, with a volume of 11,376 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a research note on Tuesday, December 17th.

Daré Bioscience Stock Performance

The company’s fifty day moving average is $3.07 and its two-hundred day moving average is $3.29. The company has a market cap of $25.06 million, a price-to-earnings ratio of -4.88 and a beta of 1.38.

Institutional Investors Weigh In On Daré Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its holdings in Daré Bioscience by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after acquiring an additional 3,593 shares during the period. Renaissance Technologies LLC boosted its position in Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 4,300 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Daré Bioscience during the 4th quarter worth approximately $52,000. Finally, AMH Equity Ltd grew its stake in shares of Daré Bioscience by 50.0% during the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 50,000 shares during the period. 6.70% of the stock is owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.